The Adaptive Experience

The time from Clonality (ID) test to first Tracking MRD test can span a longer time frame for patients with myeloma.

For how long are patients with myeloma monitored with clonoSEQ?

Initiation of clonoSEQ MRD testing will vary based on a patient’s presentation and treatment course.  For approximately half of myeloma patients, the first MRD will be evaluated within a year of diagnosis*. The timeframe for initiation of MRD for patients with myeloma may span a wider range of several years from the time of diagnosis. *Assumes ID collection date is indicative of time of diagnosis

AdaptiveExp 3

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit